Clinical stage immune-oncology company focused on the development of its targeted tumor membrane immunotherapy
Cytovation has raised €25M across 2 funding rounds from 2 investors, most recently a Series A round in Jun 2023. Based in Bergen, Norway; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2023-06-12 | Series A | €7.4M | Canica,Sandwater | View deal → |
| 2022-01-25 | Series A | €18M | Canica,Sandwater | View deal → |
